Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Nov 13, 2019 (7 years ago)

Ranitidine Oral Solution

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API.

Cause type: Nitrosamine impurity

Trace nitrosamine impurities such as NDMA, NDEA or NMBA found above the acceptable daily limit. Nitrosamines are probable human carcinogens that can form during manufacturing or storage. This is the cause behind the large valsartan, losartan and ranitidine (Zantac) recalls. All nitrosamine impurity recalls.

What was recalled

Ranitidine Oral Solution, USP, 150 mg/10 mL, [10 mL x 30 Unit Dose Cups per case, NDC: 68094-204-62; 10 mL x 100 Unit Dose Cups per case, NDC: 68094-204-61; Unit Dose Cup NDC: 68094-204-59], Rx only, Precision Dose, Inc., South Beloit, IL 61080

Affected NDCs 68094-0204-59 68094-0204-61 68094-0204-62

Compare with the code on your package — it is the most precise check available.

Drug: Ranitidine Category: Heartburn & Stomach Medication

Recalling firm
Precision Dose Inc.
Origin
IL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1004-2020 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Ranitidine recalls

See all
Class II · Moderate risk

Ranitidine 300 mg

CGMP Deviations: Presence of NDMA impurity detected in product.

Terminated Nitrosamine impurity Direct Rx NDC 61919-455-30 D-0017-2021
Class II · Moderate risk

Ranitidine 150 mg

CGMP Deviations: Presence of NDMA impurity detected in product.

Terminated Nitrosamine impurity Direct Rx NDC 61919-339-60 D-0016-2021
Class II · Moderate risk

ranitidine hydrochloride

CGMP Deviations: Received notice from supplier of potential -Nitrosodimethylamine (NDMA) amounts above established levels.

Terminated Nitrosamine impurity PD-Rx Pharmaceuticals, Inc. NDC 43063-844-14 D-0826-2020

Other recalls by Precision Dose Inc.

All 2019 recalls